Peterborough, Canada

Kawartha Centre

Alzheimer Disease

Frontotemporal Dementia

Cognitive Dysfunction

Lewy Body Disease

Mixed Dementias

Dementia

Parkinson Disease

ANAVEX2-73

EXV-802

EXV-801

Anavex Life Sciences

McGill University

Exciva GmbH

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Kawartha Centre | Peterborough, Canada

Site insights

Work at this site?

Active trials

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia (SERENADA)

Trial sponsors